Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study.

Détails

ID Serval
serval:BIB_2680D836B84F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study.
Périodique
Journal of the European Academy of Dermatology and Venereology
Auteur⸱e⸱s
Brüggen M.C., Valencak J., Stranzenbach R., Li N., Stadler R., Jonak C., Bauer W., Porkert S., Blaschke A., Meiss F., Nicolay J.P., Wehkamp U., Schlaak M., Nguyen V.A., Romani N., Cozzio A., Gayathri N., Dimitriou F., French L.E., Dummer R., Guenova E.
ISSN
1468-3083 (Electronic)
ISSN-L
0926-9959
Statut éditorial
Publié
Date de publication
07/2020
Peer-reviewed
Oui
Volume
34
Numéro
7
Pages
1489-1495
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive type of haematologic precursor malignancy primarily often manifesting in the skin. We sought to provide a thorough clinical characterization and report our experience on therapeutic approaches to BPDCN.
In the present multicentric retrospective study, we collected all BPDCN cases occurring between 05/1999 and 03/2018 in 10 secondary care centres of the German-Swiss-Austrian cutaneous lymphoma working group.
A total of 37 BPDCN cases were identified and included. Almost 90% of the patients had systemic manifestations (bone marrow, lymph nodes, peripheral blood) in addition to skin involvement. The latter presented with various types of cutaneous lesions: nodular (in more than 2/3) and bruise-like (in 1/3) skin lesions, but also maculopapular exanthema (in circa 1/6). Therapeutically, 22 patients received diverse combinations of chemotherapeutic regimens and/or radiotherapy. Despite initial responses, all of them ultimately relapsed and died from progressive disease. Eleven patients underwent haematopoietic stem cell transplantation (HSCT; autologous HSCT n = 3, allo-HSCT n = 8). The mortality rate among HSCT patients was only 33.33% with a median survival time of 60.5 months.
Our study demonstrates the clinical diversity of cutaneous BPDCN manifestations and the positive development observed after the introduction of HSCT.
Pubmed
Web of science
Création de la notice
23/01/2020 16:33
Dernière modification de la notice
02/09/2020 6:22
Données d'usage